Replies to post #798272 on NorthWest Biotherapeutics Inc (NWBO)

[sukus]

Slave1, regular folks such as most long investors are not very familiar with how this various grades of clean rooms are utilized. To be honest, I learned the most after Flipper asked you that question and you disclosed the source. Now I realized those 8k, 10q etc are choke full of information. But only those with knowledge and familiarity can divulge that for regular investors. Thank you for great insight Slave1. Much appreciated. :) :)

[dennisdave]

The Annex 1 quotes are fine nobody is disputing what GMP Grades B/C/D are used for.
What doesn’t hold up is you jumping from that to “SOW 8 completion proves Grade C rooms had to exist, be qualified, and be licensed.”

Yes: Annex 1 does say upstream prep (solution prep, sampling, dispensing) normally happens in Grade C. That part is correct.

Not correct: Pretending that “SOW 8 validation package” is an official regulatory term whose scope automatically includes every Grade-C step. It isn’t. SOW 8 is an internal Advent/NWBO label, and its exact contents are not published anywhere.

Not correct numoro dos: Claiming MHRA documentation confirms specific room layouts or licensing status. MHRA does not publish cleanroom schematics or room-by-room usage.

It’s plausible that Grade C space was involved in SOW 8, but it is not proven, and the conclusion that “Grade C rooms had to exist and be licensed” is based on assumptions about what SOW 8 covers not on Annex 1 itself.

This is what you (or your AI I dunno) are doing all the time making quantum leaps of speculation based on 25% truths